Oestrogen hormone therapy use was inversely associated with young-onset breast cancer, and oestrogen plus progestin hormone therapy was associated with higher young-onset breast cancer incidence among women with intact uterus and...
We read with great interest Jennelle C Hodge and colleagues’ Comment on the WHO Classification of Tumours1 and wish to highlight the crucial need to bridge the growing gap between diagnostic classification and therapeutic access in the...
Nobuaki Matsubara and colleagues1 and Andre P Fay and colleagues2 are to be congratulated for making the patient perspective an integral part of cancer drug development with patient-reported outcomes from the TALAPRO-2 trial.
The 50-month follow-up of LITESPARK-004, reported by Ramaprasad Srinivasan and colleagues,1 marks a pivotal advance for von Hippel-Lindau disease, a rare syndrome with limited therapies. The findings on belzutifan's durable efficacy,...
Ramaprasad Srinivasan and colleagues described good oncological outcomes coupled with acceptable toxicity following treatment with the hypoxia-inducible factor-2α (HIF-2α) inhibitor belzutifan for patients with von Hippel-Lindau...
Hughes T, Harper A, Gupta S, et al. The current and future global burden of cancer among adolescents and young adults: a population-based study. Lancet Oncol 2024; 25: 1614–24—In this Article, figure 3 has been replaced with an updated...
Romero Y, Tittenbrun Z, Trapani D, et al. The changing global landscape of national cancer control plans. Lancet Oncol 2025; 26: e46–54—In this Policy Review, the spelling of Maha Al-Ghafry's name was incorrect in the NCCP Global Review...
Van Gorp T, Moore KN, Konecny GE, et al. Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor α-positive, platinum-resistant ovarian cancer: a...
Srinivasan R, Iliopoulos O, Beckermann KE, et al. Belzutifan for von Hippel-Lindau disease-associated renal cell carcinoma and other neoplasms (LITESPARK-004): 50 months follow-up from a single-arm, phase 2 study. Lancet Oncol 2025; 26:...
Villarreal-Garza C, Aranda-Gutierrez A, Gonzalez-Sanchez DG, et al. National cancer control plans in Latin America and the Caribbean: challenges and future directions. Lancet Oncol 2025; 26: e320–30—In this Policy Review, the spelling of...
Reddy CL, Sousa C, Atun R. Benchmarking infrastructure for cancer control in Commonwealth countries: a population-based observational study. Lancet Oncol 2025; 26: 924–35—In this Article, Prof Rifat Atun should have had the additional...
The global surgical crisis has become one of the most discussed health topics since the Lancet Commission report published in 2015 because the need is massive, and the consequences are devastating both to countless personal lives and to...
It was by far the most difficult phone call of my life. Absolutely nothing can prepare you for telling your mother that she has stage 4 lung cancer. One does not need to understand the intricacies of cancer staging to feel the gravity of...
The results of the dose-expansion portion of our multicentre, open-label, phase 1b study evaluating the combination of gedatolisib, a pan-PI3K–mTORC1/2 inhibitor, with palbociclib and endocrine therapy in patients with hormone...
The RADIOSA phase 2 randomised clinical trial included 102 patients with metachronic oligometastic prostate cancer who were randomly assigned to receive either stereotactic body radiotherapy (SBRT) with 6 months of androgen deprivation...
We read with great interest the published results of the RADIOSA trial by Giulia Marvaso and colleagues.1 This well designed randomised phase 2 study represents an important effort in addressing the role of stereotactic body radiotherapy...
We read the published Article by Berend J van der Wilk and colleagues reporting the results of the SANO trial with great interest as it reveals many crucial questions regarding the optimal treatment of patients with resectable...
The validity of the SANO trial hinges on a single premise: the procedure for monitoring complete clinical response is reliable.1 Every patient randomly assigned to surgery was first confirmed to have a complete clinical response by the...
Despite the obvious interest in an organ preservation strategy for oesophageal cancer, the SANO trial, published in the report by Berend J van der Wilk and colleagues,1 has important limitations, which must be carefully considered in the...
The SANO study by Berend J van der Wilk and colleagues showed non-inferiority of the non-surgical approach if complete clinical response was reached with chemoradiation in patients with resectable oesophageal squamous cell carcinoma.1 We...
We thank Brian Housman and Raja Flores, Akhill Kapoor and colleagues, Sheraz R Markar and colleagues, and Ahmet Oruç and colleagues for their interest in the SANO trial. We are pleased to elaborate on their five key issues raised in...
We read with great interest the Lancet Oncology Editorial1 calling for a coordinated global approach to address the growing cancer burden in the face of recent cuts to international aid from high-income nations. While we agree that...
In June, 2025, the UK government announced plans to boost science and technology research and development (R&D) in the country, pledging to invest £86 billion in the sector over the next 4 years. The life sciences sector has been...
The relationship between hormone therapy (oestrogen with or without progestogen) and breast cancer risk has been widely investigated in numerous studies and meta-analyses, mainly on hormone replacement therapies for postmenopausal women....
More than 10% of new triple-negative breast cancer cases could be avoided if women breastfed or pumped for longer than 6 months, according to results of a retrospective analysis. Between 3,000 and 5,000 diagnoses could be prevented per...
This year’s Women in Medicine Summit is being held in Chicago from Sept. 18 to Sept. 20. The summit offers mentorship and networking opportunities, education, workshops, presentations and toolkits while representing over 70 specialties....
An AI system called iSeg is reshaping radiation oncology by automatically outlining lung tumors in 3D as they shift with each breath. Trained on scans from nine hospitals, the tool matched expert clinicians, flagged cancer zones some...
Many Black and Latina women frequently use lotions, soaps, shampoos and other personal care products that contain the carcinogen formaldehyde, or formaldehyde-releasing preservatives, according to study results. More than 50% of...
Smoke from wildfires and structural fires doesn t just irritate lungs it actually changes your immune system. Harvard scientists found that even healthy people exposed to smoke showed signs of immune system activation, genetic changes...
The Supreme Court decided 6-3 to protect no-cost preventive health care today, but major medical organizations warn that the ruling leaves loopholes that could be exploited. The Kennedy v. Braidwood Management Inc. case challenged the...
Researchers have found a way to observe clotting activity in blood as it happens -- without needing invasive procedures. Using a new type of microscope and artificial intelligence (AI), their study shows how platelet clumping can be...
Risk analyst Tony Cox’s work has been backed by the chemical lobby, and some health experts are alarmed An industry-backed researcher who has forged a career sowing doubt about the dangers of pollutants is attempting to use artificial...
CHICAGO — Dexrazoxane helped adolescents and young adults with cancer who received doxorubicin chemotherapy have significantly better heart function and structure years after diagnosis, according to findings presented at ASCO Annual...
When our teenage son was diagnosed with cancer, we joined the 3 million-strong army of unpaid carers in Australia. Now the TV series Dying for Sex gives caregiving the value it deserves When I started watching the Disney+ show Dying for...
Cancer Research UK says this is more than any other health condition and 350,000 years of productivity are lost People dying early of cancer costs the UK economy £10.3bn a year, more than any other health condition, a study has revealed....
Patients with certain subtypes of breast cancer may be at higher risk for death by waiting more than 42 days after their diagnosis to undergo surgery, according to study results published in Breast Cancer Research. Patients with HR+ or...
CHICAGO — International medical graduates are underrepresented in leadership roles at NCI-designated cancer centers, according to study results presented at ASCO Annual Meeting. Researchers also observed stark disparities by gender,...
Out-of-pocket expenses for bowel preparation may limit access to colonoscopy, potentially delaying diagnosis and treatment, according to a study published in Gastroenterology. “To have a test where you can identify a cancer before it...
Senators questioned Susan Monarez, PhD, about a range of topics Wednesday during a hearing to assess her nomination to be the next director of the CDC. Monarez expressed some support for HHS Secretary Robert F. Kennedy Jr.’s changes at...
More than 15% of individuals living with HIV and cancer have not received recommended first-line cancer therapy, according to results of a retrospective analysis. Among patients with HIV and cancer, those who lived in the lowest...
In a recent survey from The Ohio State University Comprehensive Cancer Center, only 13% of adults said testicular cancer is most common among men aged younger than 40 years. However, testicular cancer — which affects about 10,000...
SAN FRANCISCO — Navigational bronchoscopy was noninferior to CT-guided biopsy when assessing diagnostic accuracy in patients with lung nodules, according to findings published in The New England Journal of Medicine. Notably,...
A new AI tool, AAnet, has discovered five distinct cell types within tumors, offering a deeper look into cancer's inner diversity. This insight could transform how we treat cancer, enabling more personalized therapies that tackle every...
Keeping sex on the schedule may be its own menopause medicine: among 900 women aged 40-79, those active in the last three months reported far less dryness, pain, and irritation, while orgasm and overall satisfaction stayed rock-solid...
CHICAGO — In this video, Susana M. Campos, MD, MPH, discusses results from a single-arm phase 2 study of the concurrent treatment of vulvar cancer with chemoradiation and pembrolizumab. Patients who underwent treatment with...
CHICAGO — In this video, Susana M. Campos, MD, MPH, discusses results from the final analysis of the phase 3 A18 study in advanced cervical cancer, presented at ASCO Annual Meeting. The ENGOT-cx11/GOG-3047/KEYNOTE-A18 trial evaluated...
CHICAGO — In this video, Susana M. Campos, MD, MPH, discusses new research on adding metformin to letrozole/abemaciclib for the treatment of estrogen receptor-positive, recurrent endometrial cancer. The data presented at ASCO Annual...
“Push through.” Noelle K. LoConte, MD, FASCO, repeated that message to herself over and over again. The clinic had limited staff due to a national holiday, and LoConte, associate professor in the division of hematology, medical oncology...
Rectal location and timing of diagnosis had minimal impact on cancer-specific and all-cause mortality rates for patients with postcolonoscopy colorectal cancer, according to a cohort study published in JAMA Network Open. Studies often...